Cantor Fitzgerald Reiterates Overweight on Kura Oncology, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA) and maintained a $30 price target.
July 21, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Kura Oncology and maintained a $30 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Kura Oncology. The maintained price target of $30 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100